WHO ICTRP trial
Open Label Study of Subcutaneous Omacetaxine in Patients With Advanced Chronic…
ACTRN12609000377235 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12609000377235 |
|---|---|
| Public title | Open Label Study of Subcutaneous Omacetaxine in Patients With Advanced Chronic Myeloid Leukemia. |
| Scientific title | A Phase II Open-Label Study of the Subcutaneous Administration of Omacetaxine in the Treatment of Patients With Chronic Myeloid Leukemia (CML) Who Have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy. |
| Primary sponsor | ChemGenex Pharmaceuticals Inc. |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 / Phase 3 |
| Countries | Australia;United States of America;Canada;France;Germany;United Kingdom;Hungary;Poland;Singapore;India |
| Conditions | Chronic Myeloid Leukemia; Chronic Myeloid Leukemia;Cancer - Leukaemia - Chronic leukaemia |
| Interventions | Omacetaxine mepesuccinate Patient will be treated with omacetaxine in treatment cycles of 28 days duration. There will be no breaks between treatment cycles and the cycles will continue for upto 24 months. Dose = 1.25 mg/m2 twice daily for… |
| Registration date | May 28, 2009 |
| Target size | 100 |
| Secondary IDs | CGX-635-CML-203 (ChemGenex Pharmaceuticals);ClinicalTrials.gov, NCT00462943 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: